News and Media

Latest News Release
01/31/2024

Transaction creates increased clinical and economic value for 11,500 specialty providers, including more than 7,000 physicians across 1,200 independent physician practices Transaction creates...

Top feature box IMAGE ONLY - COMPANY NEWS

Press Releases

Cardinal Health Announces Collaborative Effort With
Z-Medica to Offer Clinically Proven Family of Hemostatic Products
11/28/2012

DUBLIN, Ohio, Nov. 28, 2012 — Cardinal Health today announced a collaboration with Z-Medica that grants Cardinal Health exclusive rights to a family of hemostatic products for catheterization and interventional radiology procedures.

Under the terms of this collaboration, Cardinal Health will have exclusive rights to offer health care providers access to clinically-proven, effective, interventional hemostatic products including the QuikClot® Interventional Hemostatic Bandage™ for femoral procedures,  QuikClot® Radial Hemostatic Bandage™ for radial procedures, and QuikClot® Interventional Hemostatic Bandage™ with a Y-slit for use around central and PICC lines. These products will carry both the Cardinal Health and QuikClot® brand names.

In addition, Cardinal Health will represent and distribute Z-Medica’s other professional health care hemostatic products suitable for managing traumatic bleeding.  

“At Cardinal Health we continually look for opportunities to bring healthcare providers clinically tested products that can help improve the quality of care,” said Lisa Ashby, president, Category Management at Cardinal Health “We are proud to jointly market QuikClot® products, and we’re confident that customers will be pleased with the substantial amount of clinical evidence that supports use of the QuikClot® family of hemostatic products.”

In clinical studies, Z-Medica QuikClot® hemostatic agents have been shown to deliver superior bleeding control in catheterization procedures and interventional radiology as well as traumatic and general healthcare applications. They have proven to be 98 percent effective in controlling interventional access site bleeding and 100 percent effective in interventional radiology, with no radial artery occlusion. When used in combination with applied pressure, QuikClot® products achieve clotting in five to eight minutes for most patients. 

All QuikClot® bandages conform readily to the wound to absorb blood and maintain their integrity. QuikClot®Combat Gauze is the only product carried by all branches of the US Military to control life-threatening hemorrhage.

“QuikClot® has been shown to control bleeding quickly, safely and effectively in some of the most severe situations, including military combat and trauma,´ said Larry Hicks, Z-Medica’s President and Chief Executive Officer. “Our products are easy to use and store, making them the ideal option for healthcare professionals who want to provide the highest levels of bleeding control for their patients quickly and effectively. We are very pleased that Cardinal Health, a global leader in health care, has recognized the important advantages that QuikClot® delivers for both health care providers and patients. We are excited to work closely with Cardinal Health.”

The QuikClot® family of hemostatic products utilize kaolin, an inert mineral clinically proven to stop arterial and traumatic bleeding and accelerate the clotting process. QuikClot® products contain no animal components, have been used safely in cosmetic and consumer products, and have no contraindications.

About Cardinal Health

Headquartered in Dublin, Ohio, Cardinal Health, Inc. (NYSE: CAH) is a $108 billion health care services company that improves the cost-effectiveness of health care. As the business behind health care, Cardinal Health helps pharmacies, hospitals, ambulatory surgery centers and physician offices focus on patient care while  reducing costs, enhancing efficiency and improving quality. Cardinal Health is an essential link in the health care supply chain, providing pharmaceuticals and medical products to more than 60,000 locations each day. The company is also a leading manufacturer of medical and surgical products, including gloves, surgical apparel and fluid management products. In addition, the company supports the growing diagnostic industry by supplying medical products to clinical laboratories and operating the nation's largest network of radiopharmacies that dispense products to aid in the early diagnosis and treatment of disease. Ranked #21 on the Fortune 500, Cardinal Health employs more than 30,000 people worldwide. More information about the company may be found at cardinalhealth.com and @CardinalHealth on Twitter.

More Company News
11/20/2024

Next generation of the Kendall™ SCD Series delivers an all-in-one solution for deep vein thrombosis and pulmonary embolism prevention DUBLIN, Ohio, Nov. 20, 2024 /PRNewswire/ -- Cardinal Health...

11/11/2024

Acquisition of a majority stake in GI Alliance, the country's leading gastroenterology management services organization, to accelerate Cardinal Health's multi-specialty growth strategy Acquisition...

11/05/2024

Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved a quarterly dividend of $0.5056 per share out of the Company's capital surplus. The dividend will be payable on...

11/01/2024

Revenue decreased 4% to $52.3 billion; revenue increased 15% excluding the impact of the previously communicated large customer contract expiration GAAP1 operating earnings were $568 million; GAAP...

View all company news »